DRAFT PROGRAMME 24‒26 October | Lisboa Congress Centre, Portugal www.lisbonaddictions.eu | #LxAddictions17 | |
DAY 1 TUESDAY 24 OCTOBER
08:00 Arrival and registration
09:00 – 10:00 INAUGURAL SESSIONS Science to policy Chair: Alison Ritter, Australia Policy to science Chair: Werner Sipp, Germany
Henrietta Bowden-Jones, Imperial College London, United Kingdom Chloé Carpentier, United Nations Office on Drugs and Crime
Alexandre Quintanilha, Chair, Parliamentary Commission on Education and Science, Torbjorn Brekke, Pompidou Group Portugal Vladimir Poznyak, World Health Organization Jallal Toufiq, The Moroccan Observatory on Drugs and Addiction, Morocco Floriana Sipala, European Commission
10:00 – 10:30 PLENARY SESSION I (FEEDBACK FROM INAUGURAL SESSIONS) Chairs: Alexis Goosdeel, EMCDDA and João Goulão, SICAD Alison Ritter, National Drug and Alcohol Research Centre, Australia
Werner Sipp, Former President International Narcotics Control Board, Germany
10:30 – 11:00 Opening ceremony
11:00 – 11:30 Coffee break
1 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
11:30 – 13:00 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 1 PAPER SESSION 2 PAPER SESSION 3 PAPER SESSION 4 PAPER SESSION 5 Alcohol - informing prevention The measurement of problems and A focus on pharmacotherapy Ageing and intergenerational issues Gambling - behavioural insights and policy trends − Law of alcohol. Two sides of the − Measuring problematic cannabis − Patient centered care for injectable opioid − Opioid treatment outcomes in − Problem gambling in coin: consumers and retailers. use in the general population: assisted treatment. Kirsten Marchand, older adults: a review of the adolescence: an analysis Elsa Lavado, Portugal conception, use and future of the Canada literature. Anne Marie Carew, conducted from the actor’s − Alcohol marketing: how to cannabis abuse screening test − Orienting the appropriate treatment of pain Ireland perspective. Annie-Claude regulate? A comparative analysis. (CAST). Stéphane Legleye, France in detained drug users: indications from a − Mortality and causes of death in Savard, Canada Marieke Vlaemynck, Belgium − Changes in cultural patterns of retrospective study. Felice Nava, Italy an ageing Norwegian OMT cohort. − Factors contributing to the − Attitudes towards alcohol policy drugs use throughout three − Response to treatment among indigenous Ivar Skeie, Norway normalisation of gambling: a across Europe, results of the generations of the Portuguese people receiving injectable − Case management for older drug qualitative study of international RARHA seas study. Zsuzsanna population - 1950, 1975 and 2000. diacetylmorphine or hydromorphone in a users. Martin Schmid, Germany gambling experts. Samantha Elekes, Poland Casimiro Balsa, Portugal randomized controlled trial for the − Ageing drug users a new challenge Thomas, Australia − alcohol marketing in Portugal: − Cannabis epidemic or return of treatment of long-term opioid-dependence. for drug treatment programmes in − How do gambling products alcohol industry and government opoid problems or decrease of Heather Palis, Canada Slovenia. Milan Krek, Slovenia which are provided in ‘family strategies in the 21st century. high risk drug use among young − The impact of benzodiazepine use in − Explanations for intergenerational friendly’ venues, shape young Hilson Cunha Filho, Portugal adults in Austria. Martin Busch, patients enrolled in opioid agonist therapy transference of addiction: people’s gambling consumption − Alcohol and illegal drugs: Austria in Ontario, Canada. Joseph Eibl, Canada perspective of the person with intentions? A qualitative study of estimating social cost in − Longitudinal trajectories of − The effects of prescribing varenicline on parent(s) who suffer from children in Australia. Amy Catalonia. Vincenzo Alberto Vella, polydrug use among adolescents: longer-term health outcomes: an addiction. Margreet van der Meer, Bestman, Australia Spain two years follow-up. Víctor observational cohort study using electronic Netherlands − Emotional characteristics of − Alcohol and other drug use Martínez-Loredo, Spain medical records. Kyla Thomas, United − Children of parents who use gamblers’ relatives. Paula among the working population in − Treatment demand indicator: Kingdom substance: parents who use and Jauregui, Spain Belgium: prevalence and job experience of its implementation − Exploration of the benefits of methadone grandparents who care, − Female pathological gamblers: related consequences. Marie- in Nigeria. Dominique Lopez, India treatment for dual users of heroin and crack perspectives of needs, risks and characteristics and obstacles for Claire Lambrechts, Belgium who inject or have previously injected drugs protective factors. Karen Galligan, treatment. Andrea Wöhr, - preliminary findings. Felicia Heidebrecht, Ireland Germany United Kingdom − Online sports betting advertising − SOF/VEL/VOX for 8 or 12 weeks is well and gambling disorder: a tolerated and results in high SVR12 rates in content analysis approach. Hibai patients receiving opioid substitution Lopez-Gonzalez, United Kingdom therapy. Jason Grebely, Australia
2 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
STRUCTURED SESSION 1 STRUCTURED SESSION 2 STRUCTURED SESSION 3 STRUCTURED SESSION 4 STRUCTURED SESSION 5 Social cognition and interaction in Understanding the clinical toxicology The Portuguese decriminalisation Setting standards in the addiction Symposium on the future of substance addiction of novel psychoactive substances model: a comprehensive approach field: a view from Europe addiction research: an overview Chair: Boris Quednow, Switzerland (NPS) Chair: Sofia Albuquerque, Portugal Chair: Antoni Gual, Spain Chair: Robert West, United Kingdom Co-Chair: Antonio Verdejo-Garcia, Chair: David Wood, United Kingdom Co-Chair: Geert Dom, Belgium Australia − Dose-related effects of − Details to be confirmed. − Decriminalisation Policy and the − An empirical basis to diagnose − Symposium: methamphetamine use on social role of the Commissions for the gambling and gaming disorders in John Holmes, United Kingdom cognition. Antonio Verdejo-Garcia, Dissuasion of Drug Addiction. ICD-11. Karl Mann, Germany Joanne Neale, United Kingdom Australia Américo Gegaloto, Portugal − An overview of European Addiction Felix Naughton, United Kingdom − Mind-reading impairment in crack- − Guidelines for Dissuasion Clinical guidelines. Connor Farren, John Marsden, United Kingdom cocaine users: an fMRI study of the Intervention: an health and Ireland − Titles to be confirmed. moderator effects of early life stress. preventive approach. Raquel Lopes, − The legal status of medical and Rodrigo Grassi-Oliveira, Brazil Portugal recreational use of cannabis − Emotion, alcohol and addiction. − The Dissuasion intervention at the throughout Europe. Jørgen Salvatore Campanella, Belgium Commissions for the Dissuasion of Bramness, Norway − Compassion and social cognition in Drug Addiction of Porto, priority heroin users: describing deficits and groups and the role of external developing treatments. Charles stakeholders. Purificação Anjos, Morgan, United Kingdom Portugal − Effects of non-medical prescription − Portuguese Commissions for the opioid use on social cognition and Dissuasion of Drug Addiction: social pain. Sara Kroll, Switzerland perspectives of indicted drug users on their role in drug use. Ludmila Carapinha, Portugal − Drug users’ assessment of the enforcement of Portuguese drug decriminalisation law and predictors of drug use. Jorge Quintas, Portugal
12:45 – 14:15 SPONSORED SESSIONS
Lunch boxes available between 13:00 and 14:30
3 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
13:15 – 14:15 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 6 PAPER SESSION 7 PAPER SESSION 8 PAPER SESSION 9 Concepts and constructs Drug use and infectious diseases: reviewing the evidence NPS - a challenge for responses Inequalities
− A transdiagnostic dimensional − Injecting and sexual risk-taking amongst people who inject − The German new psychoactive substance − A review of the factors associated with approach to addiction: an drugs: a global review. Amy Peacock, Australia law (NPSG): perceived and expected mothers who use substances losing care of international Delphi consensus − Needle syringe programmes and opioid substitution outcomes in the first stage of their children. Martha Canfield, United study. Murat Yücel, Australia therapy for prevention HCV transmission among people implementation. Tessa-Virginia Kingdom − Putting the brain in its place: who inject drugs: Cochrane systematic review. Matthew Hannemann, Germany − Social determinants of drug-related mortality arguments from ethics and Hickman, United Kingdom − French media and new psychoactive among general population. Sanna Rönkä, philosophy of science. Jaakko − Recent incarceration and risk of hepatitis C and HIV substances: is a new discourse emerging. Finland Kuorikoski and Susanne Uusitalo, transmission amongst people who inject drugs: a systematic Julie-Emilie Adès, France − Boxing clever: evaluation of a community Finland review and meta-analysis. Jack Stone, United Kingdom − New psychoactive substances: current based inter-agency education and fitness − Non problematic illicit drug use: a − A systematic review and meta-analysis of psychosocial health-related practices and challenges in substance use intervention program. Sarah less known but not less important interventions to reduce drug and sexual blood borne virus responding to use and harms in Europe. Morton, Ireland phenomenon. Olga Cruz, Portugal risk behaviours among people who inject drugs. Gail Alessandro Pirona, EMCDDA − The representation of non-Belgians in national − Constructing alcohol-related Gilchrist, United Kingdom − Responses to the problem of ‘legal highs’ drug treatment. Eva Blomme, Belgium problems – attitudes of social − HIV prevention, treatment and care for people who inject in Poland and their consequences. − Understanding addiction: a health inequalities workers and their clients. Elina drugs: a systematic review of coverage of interventions. Krzysztof Krajewski, Poland and social harms perspective. Aileen Renko, Finland Sarah Larney, Australia O´Gorman, United Kingdom STRUCTURED SESSION 6 STRUCTURED SESSION 7 STRUCTURED SESSION 8 STRUCTURED SESSION 9 European quality standards in drug Assessment of risky cannabis use and related Gambling and gaming 2.0: one and the same? Global surveillance of prescription drug misuse: demand reduction: how to monitor consequences Chair: Sylvia Kairouz, Canada multi-system data networks throughout Europe, implementation? Chair: Hugo López Pelayo, Spain United Kingdom and North America Chair: Marica Ferri, EMCDDA Chair: Jody Green, United States-Canada − Panel discussion: − Definitions of risky and problematic cannabis − Reframing the gambling field: epistemological − The evolution of the opioid abuse epidemic in Matej Kosir, Slovenia use: a systematic review. Cristina Casajuana, and methodological shifts in the study of the North America. Richard Dart, United States-Canada Harry Sunmall, United Kingdom Spain gambling/gaming convergence. Sylvia Kairouz, − The landscape of prescription drug misuse in the Lubomir Okhrulica, Slovak Republic − Assessment of cannabis use disorders: a Canada U.K. David Wood, United Kingdom Dave Liddle, Scotland systematic review of screening and diagnostic − Business models of gaming and gambling and − The European experience: prescription drug misuse − Titles to be confirmed. instruments. Hugo López-Pelayo, Spain how they converge. Ingo Fiedler, Germany in France, Germany, Italy and Spain. Jody Green, − Standard Joint Unit as a tool for assessing − Overlapping between gambling and some form United States-Canada risky cannabis use. Antoni Gual, Spain of gaming in the Internet world: first results of a − Experience of the EURO-DEN Plus: ED presentations Discussant: Mercè Balcells, Spain cross-national survey. Jean-Michel Costes, France with acute toxicity related to misuse of ‘licensed
4 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
− Spectrum model of social casino medicines’. Paul Dargan, United Kingdom gaming/gambling: Understanding the convergence. Jennifer Reynolds, Canada
14:30 – 16:00 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 10 PAPER SESSION 11 PAPER SESSION 12 PAPER SESSION 13 Addressing smoking and related behaviours Alcohol - assessment Addiction - the link with crime and offending Improving responses to HCV − Relative reinforcing efficacy of cigarettes − Validation of alcohol consumption self-reports − Promoting recovery and desistance among − Factors predicting usage of low dead space among depressed and non-depressed in the Munich composite international primary drug users involved in offending. syringes amongst people who inject drugs in smokers. Alba González-Roz, Spain diagnostic interview (M-CIDI). Sören Kuitunen- Charlotte Colman, Belgium the United Kingdom, and the association − Predicting treatment outcome: an examination Paul, Germany − Addiction, comorbidity and criminal with hepatitis C prevalence. Adam Trickey, of the mechanism of action of two pre-quit − Screening for moderate/high risk alcohol use recidivism of female systematic offenders. United Kingdom smoking cessation pharmacotherapies. Stuart among opioid dependent patients on Eric Blaauw, Netherlands − Efficacy and safety of sofosbuvir/velpatasvir Ferguson, Australia buprenorphine maintenance: a clinical and − Predicting offending after residential in people with chronic hepatitis C virus − The efficacy of behavioural activation and alcohol-biomarker study. Suresh Thapaliya, rehabilitation. Birgitte Thylstrup, Denmark infection and recent injecting drug use: the contingency management for cigarette Nepal − ‘You, of all people’: interviews with ten simplify study. Jason Grebely, Australia smokers with depression: a randomized − Factors related to binge drinking in nurses who lost their medical license due to − Hepatitis Antibody and RNA prevalence controlled trial. Alba González-Roz, Spain adolescence: integrative literature review. prescription drug use and theft from the among opiate substituted patients in − Are smoking and e-cigarette use prospectively Tereza Barroso, Portugal work place. Oda Sjovoll, Norway Germany: epidemiological data collected associated with one another? A longitudinal − Context of daily drinking in 18 European − Substance abuse and violent crime: an under real life practice circumstances. Bernd study of young people in Great Britain. countries. Findings of the RARHA seas project. analysis of the psychopharmacological Schulte, Germany Katherine East, United Kingdom Katarzyna Okulicz-Kozaryn, Poland model in a sample of United States inmates. − Prison history and drug-related problems in − Individual, interpersonal and environmental − Еmotion regulation and cognitive control in Michele Pich, United States people who inject drugs – associations of risk factors associated with tobacco use [daily patients with alcohol dependence. Svetlana − ´If the person doesn’t drink they are one HIV and HCV with prison history in the smoking] among Kosovar youth. Zamira Klimanova, Russia person, if they drink they are another´. How European Union and beyond. Lucas Wiessing, Hyseni Duraku, Kosovo* − Nunc est bibendum! The effects of placebo men in treatment for substance use in EMCDDA − Young adults report increased pleasure from and moderate dose alcohol on attentional England and Brazil account for perpetrating − Modelling the impact of interventions using e-cigarettes and smoking tobacco bias, inhibitory control and subjective craving. intimate partner violence. Polly Radcliffe, targeting high-risk populations on the cigarettes when drinking alcohol. Johannes Adam McNeill, United Kingdom United Kingdom general hepatitis epidemic in resource- Thrul, United States − Cognitive functioning in patients with abuse of limited settings. Aaron Lim, United Kingdom alcohol and intoxicating substances in mood − Promoting hepatitis C virus (HCV) * This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the disorders and influence of age on onset therapeutic adherence in outreach settings: Kosovo declaration of independence. substance use. Irma Höijer, Finland project evaluation. Teresa Sousa, Portugal
5 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
PAPER SESSION 14 PAPER SESSION 15 PAPER SESSION 16 PAPER SESSION 17 Perspectives on policy New psychoactive substances - trends Prevention - theory and practice Integrating care models and partnerships and developments − Evaluating the effect of full legalization on the medical − New psychoactive substance use − The problem with ‘responsible gambling’: a − Multi-setting community-based interventions cannabis market in Colorado: implications for among regular psychostimulant study of attitudes towards and experiences to reduce population level harms arising from prescription policy. Davide Fortin, France users in Australia, 2010-2017. Rachel of personal responsibility discourses in alcohol and other drug use. Emily Stockings, − Cyprus national strategy assessment throughout drug Sutherland, Australia people experiencing gambling addiction. Australia treatment services evaluation study: methodology, − New trends in drug use in Germany? Helen Miller, Australia − Successful application of a cross-sectoral principal findings and perspectives. Gerasimos The use of new psychoactive − Learning from success: the implementation integrated care approach to addiction and Papanastasatos, Greece substances and methamphetamine and scientific evaluation of the Israeli homeless services – the experience from − Developing an evidence informed local drug strategy: in five federal states. Elena Gomes national comprehensive program to southern Ireland. Joe Kirby, Ireland identifying the prevalence, risks and protective factors de Matos, Germany reduce alcohol problem drinking among − Efficacy of case management for persons with for children of parents who use drugs. Catherine − The EU early warning system – 20 children and youth 2010-2016. Yossi Harel- substance use disorders: a Cochrane update. Comiskey, Ireland years of monitoring new Fisch, Israel Wouter Vanderplasschen, Belgium − Estimating the current and potential future impact of the psychoactive substances in Europe. − Online prevention of substance abuse − Heplink: integrating hepatitis C treatment in Mexican drug law reform on HIV incidence among Rachel Christie, EMCDDA among students with eCHUG-D. Marion primary care. Walter Cullen, Ireland people who inject drugs (PWID) in Tijuana, Mexico, using − New psychoactive substances (NPS) Laging, Germany − Exploring fast track opiate agonist treatment mathematical modelling. Annick Borquez, United States in Portugal – trends and − Prevention systems in Europe: how can (OAT) for homeless, American, opiate mis- − Evaluation of drug laws and policies by means of new approaches. Susana Henriques, they be described, assessed and improved. users. Marcia Tanur, United States indicators and data regarding minor subjects, PDUs and Portugal Gregor Burkhart, EMCDDA − The new privatized market for alcohol and arrested dealers. Carla Rossi, Italy − Teenagers and NPS in Poland – − High school finalists trip: preventing risk drug treatment – growing challenges in regard − Implications of monitoring alcohol marketing for public attitudes and behaviors. Tomasz behaviour with young people. Irma Brito, to inconsistent principles and fumbling health and policy. Carina Ferreira-Borges, Portugal Białas, Poland Portugal steering models. Jessica Storbjörk, Sweden STRUCTURED SESSION 10 STRUCTURED SESSION 11 STRUCTURED SESSION 12 Biomarkers in addiction: the experience of Lessons learned from the recent HIV outbreaks in Europe among people who Addiction in daily life: mobile assessment and treatment the Spanish network on addiction research inject drugs Chair: Ingmar Franken, Netherlands Chair: Fernando Rodriguez de Fonseca, Spain Chair: Don Des Jarlais, United States and Vana Sypsa, Greece Marta Torrens, Spain − Lessons learned from the recent snow blow related HIV outbreak in Dublin. − EMA in the field of addiction. Joel Swendsen, France Marta Rodriguez-Arias, Spain Margaret Fitzgerald, Ireland − Cognitive measures in EMA research. Andy Jones, United Kingdom Maribel Colado, Spain − The HIV outbreak among PWID in Romania 2012-2016. Cristina Fierbinteanu, − The use of EMA in a clinical trial. Ilse Verveer, Netherlands Olga Valverde, Spain Romania − Smartphone apps for the treatment of addictive disorders. − Titles to be confirmed. − An outbreak of HIV infection among people who inject drugs in Glasgow Yasser Khazaal, Switzerland (United Kingdom). Andrew McAuley and Catriona Milosevic, United Kingdom Discussants: Ingmar Franken, Netherlands and Matt Field, United − An outbreak of HIV infection among people who inject drugs in Athens, Kingdom
6 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
Greece: rapid intervention and lessons learned. Vana Sypsa, Greece − Injection of cocaine is associated with recent HIV outbreak in People Who Inject Drugs in Luxembourg. Carole Devaux, Luxembourg
16:00 – 16:30 Coffee break
16:30 – 18:00 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 18 PAPER SESSION 19 PAPER SESSION 20 PAPER SESSION 21 PAPER SESSION 22 Moving interventions online A focus on methodology Basic science - new findings Alcohol - issues for treatment Local perspectives - local responses − Online problem gamblers’ − Estimating alcohol annual − Alteration to hippocampal volume and − Is dialectical behavior therapy skills training a − Peer education ‘youth for motivation to change: a consumption on the basis of shape in cannabis dependence: a multisite therapeutic alternative in alcohol use disorder youth’. Zrinka Puharić, qualitative study with population survey. Janusz study. Yann Chye, Australia and personality disorders comorbidity Croatia implications for the design of Sieroslawski, Poland − Weighing the evidence: a systematic treatment? Marco Cavicchioli, Italy − Drug addiction in Senegal, online interventions. Ayna − Beyond informed consent: ethical review on long-term neurocognitive effects − Will this adult patient go into severe alcohol the case of Casamance. Johansen, Norway dilemmas in a clinical trial testing of cannabis use in abstinent adolescents withdrawal? Systematic review and meta- Benoît Tine, Senegal − Assessing readiness to the effectiveness of injectable and adults. Florian Ganzer, Germany analysis. Jan Klimas, Ireland − Why getting sober isn´t implement web-based opioid assisted treatment for long- − Locomotor sensitization to cocaine and − Outpatient addiction treatment for alcohol use enough? Multiple interventions for the term opioid dependence. Kirsten methamphetamine in drosophila disorder: what makes patients who dropped addictions among the prevention and/or reduction Marchand, Canada melanogaster. Rozi Andretic Waldowski, out different from those who did not? Vincent hard to reach population of substance use at ten − Different modes of data collection, Croatia Wagner, France in the ‘largest open drug universities in Germany – different results. Clara Vital, − Using functional near infrared − Effectiveness of brief intervention for scene’ in Israel. Hagit results of the DIOS-project. Portugal spectroscopy to identify neural activity moderate/high risk alcohol use among Bonny-Noach, Israel Claudia Pischke, Germany − The absurdity of asking the people during cue-elicited in a real-life setting. patients on buprenorphine maintenance: a − Interaction and interplay − Characteristics of gamblers about opinions they do not yet Flora Colledge, Switzerland clinical and alcohol-biomarker study. Suresh between rapid assessment using a national help-line for have. Alfred Uhl, Austria − Accumulation of highly stable δfosb- Thapaliya, Nepal and a local drug monitor. problem gambling in France − Ethical inquiry into cannabis pilot isoforms and its targets inside the reward − Characteristics and significance of Liv Flesland, Norway between 2010 and 2015. projects. Susanne Uusitalo, Finland system of chronic drug abusers. Monika professional-led support groups in the − Public expenditure on Stéphane Darbeda, France − The use of licit and illicit drugs and Seltenhammer, Austria treatment of alcoholism. Ana Opačić, Croatia drug treatment and − YouTube presence of an the workplace: defining a model of − Dependent anabolic-androgenic steroid − Improving the identification and treatment of associated comorbidities: addiction medicine service: survey questionnaire. Cláudia users have larger nucleus accumbens problem drug and alcohol users in somatic the case-study of what works? Gerard Calzada, Urbano, Portugal volume and thinner cortex compared to healthcare - a cross-sectional comparative Bergamo. Sabrina Switzerland non-dependent users. Lisa Evju Hauger, study. Danil Gamboa, Norway Molinaro, Italy Norway
7 / 20 Draft 28 July 2017
DAY 1 TUESDAY 24 OCTOBER
STRUCTURED SESSION 13 STRUCTURED SESSION 14 STRUCTURED SESSION 15 STRUCTURED SESSION 16 STRUCTURED SESSION 17 Anabolic androgenic steroids (AAS) Advancing theory and treatment Prevalence of alcohol, tobacco and The future of addiction Attune: understanding pathways to stimulant and associated drugs: new insights approaches for males in substance drug use in the mediterranean research: discussion use: a mixed-methods examination of the into the extent of use, harms and use treatment who perpetrate region among school aged Chair: Robert West, United individual, social and cultural factors shaping responses intimate partner violence children - the MEDSPAD network Kingdom illicit stimulant use across Europe Chair: James McVeigh, United Kingdom Chair: Gail Gilchrist, United Kingdom Chair: Richard Muscat, Malta Chair: Marcus Martens, Germany − AAS and substance use among − Meta-ethnography of 24 qualitative − MedSPAD Network history. − Details to be confirmed. − Introduction to the EU ATTUNE study: an prisoners: findings from a studies to describe the role that Florence Mabileau, Pompidou overview of the mixed method design and its Norwegian national prison Survey. substance use may play in IPV Group rationale. Marcus Martens, Germany Ingrid Havnes, Norway perpetration. Fay Dennis, United − MedSPAD Regional key findings. − Which individual, social and environmental − A typology of AAS use by men in Kingdom Valeria Siciliano, Italy influences shape different pathways of fitness and strength-training − Qualitative interviews conducted in − MedSPAD Regional key findings. amphetamine type stimulant use over the life environments. Dimitris Liokaftos, England describing 45 substance- Elisa Benedetti, Germany course? A systematic review and thematic Denmark using perpetrators’ and their − Legal, social and economic synthesis of the qualitative literature. Amy − An investigation of cognitive ex/current-partners’ narratives of aspects that impact on O´Donnell and Michelle Addison, United functions in long-term AAS using what contributes to IPV. Polly prevalence. Salah Abdennouri, Kingdom and non-using weightlifters. Astrid Radcliffe, United Kingdom Algeria, Menan Rabie, Egypt, − ATS users’ experiences of transitions into Bjørnebekk, Norway − Systematic review of effective Yossi Harel-Fisch, Israel, Jallal diverse patterns of stimulant use: results from − Injection related harms and interventions to reduce IPV Toufiq, Morocco, and Hajer in-depth qualitative interviews in five EU infections among people injecting perpetration among male substance Aounallah-Skhiri, Tunisia countries. Roman Gabrhelik, Czech Republic, AAS and associated drugs in the users and what works for whom. Discussion Panel: Meni Malliori, Heike Zurhold, Netherlands and Michal United Kingdom. Vivian Hope, Danielle Stephens-Lewis and Amy Greece, Florence Mabileau, Szulawski, Poland United Kingdom Johnson, United Kingdom Pompidou Group, Valeria Siciliano, − Exploring trajectories of amphetamine use − Treatment and information needs Italy, and Richard Muscat, Malta from the life event and substance use charts among AAS users with health applied in qualitative interviews with stimulant problems. Christine Wisløff, Norway and non-stimulant users. Nienke Liebregts, Discussion: Marie-Claire Van Hout, Netherlands and Katrin Schiffer, Netherlands United Kingdom. − Design, methods and instruments of the forthcoming quantitative study arm: structured questionnaire of 2000 ATS users across Europe. Magdalena Rowicka, Poland and Moritz Rosenkranz, Germany
18:00 Conference Cocktail
8 / 20 Draft 28 July 2017
DAY 2 WEDNESDAY 25 OCTOBER
09:00 – 10:30 PLENARY SESSION II MEASURING ADDICTIONS — A QUESTION OF SCALE Chair: Sabrina Molinaro, Italy Global burden of addictions. Louisa Degenhardt, Australia Addiction-related crime and ‘harms to the society’. Letizia Paoli, Belgium Opioids and other drug issues. Christopher Jones, United States
10:30 – 11:00 Coffee break
11:00 – 12:30 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 23 PAPER SESSION 24 PAPER SESSION 25 PAPER SESSION 26 PAPER SESSION 27 Cannabis - shifts in the regulatory Understanding drug-related Alcohol - targeting the young Improving responses to opioid users and Market developments and their framework mortality PWID impact − Understanding the new cannabis − Trends in injector deaths in − Attentional bias between light and − Establishing a postal based harm − To use or not to use? An exploration regulatory frameworks. Ivana Ireland, as recorded by the heavy drinking college students. reduction service for hard-to-reach of cannabis use motives and Obradovic, France national drugs-related deaths Alexandra Ghita, Spain injecting drug users. Thomas Nefau, constraints. Liz Temple, Australia − Relation of legalization of index, 1998-2014. Therese Lynn, − Energy drink and alcohol mixed France − Are changes in cannabis potency cannabis for medical purposes Ireland energy drink use among high school − Documenting barriers to access HCV care associated with subsequent and adolescent use in the United − Mortality and causes of death in adolescents: association with risk and treatment: a peer-led research. João admissions to drug treatment? Tom States. William Crano, United the Norwegian national OMT- taking behavior, social Santa Maria, Portugal Freeman, United Kingdom States programme in the years 2014 characteristics. Sabrina Molinaro, − Diagnosis and treatment of HCV − The displacement of illicit drug − Cannabis as medicine in and 2015. Anne Bech, Norway Italy infection: a tool of engagement for markets from the Netherlands to Germany. Ingo Ilja Michels, − Mortality risk during and after − Sensation seeking and adolescent people who inject drugs (PWID). Brian Belgium: perception or reality? Freja Germany opioid substitution treatment: alcohol use: exploring the mediating Conway, Canada de Middeleer, Belgium − Worldwide drug use systematic review and meta- role of unstructured socializing with − Evaluating the impact of opioid − Impact of the change in poppers decriminalization practices: a analysis of cohort studies. Marica peers. Sharon Sznitman, Israel substitution treatment on mortality – a regulation on their use in France. scoping review. Marta Pinto, Ferri, EMCDDA − Prevention of alcohol abuse in CPRD cohort study comparing Cécile Chevallier, France Portugal − Opioid overdose mortality trends college students. Carla Rocha, community prescribing of buprenorphine − A dramatic increase in cannabis use − A work in progress: in Australia. Amanda Roxburgh, Portugal and methadone in United Kingdom. among young and adult populations understanding the development Australia − Alcohol: raising awareness and Matthew Hickman, United Kingdom in Israel: the ’normalization’ effects of the cannabis social club model − Mortality and causes of death action research on heavy episodic − The German medical association’s revised of the intense public debates in Belgium and its current key among polydrug users. Karoliina drinking among low income youth guidelines for OST: legal framework, regarding cannabis legalization and features. Mafalda Pardal, Belgium Karjalainen, Finland and young adults in southern treatment regulations and scientific medicalization. Yossi Harel-Fisch, Europe. Helena Carvalho, Portugal rationale. Wilfried Kunstmann, Germany Israel − Investigating regulatory − Rates, causes and predictors of − Associations between personal and − Towards a long-term perspective: − User characteristics and effect
9 / 20 Draft 28 July 2017
DAY 2 WEDNESDAY 25 OCTOBER
approaches to medicinal and death among drug users in perceived peer use and attitudes analysis of treatment participation in profiles of butane hash oil: an recreational cannabis. Chris France: invisibility of fatal towards substance use among opioid substitution therapy in four extremely high-potency cannabis Wilkins, New Zealand overdoses. Anne-Claire Brisacier, German university students- European regions. Carlos Nordt, concentrate. Gary Chan, Australia France findings of a multi-centre cluster- Switzerland − Violence, fraud, legal risks and − Rates, characteristics and controlled intervention trial. Stefanie − The German legal system and the avoidance strategies in small-scale circumstances of Maria Helmer, Germany regulatory approach governing the drug markets. Results from social methamphetamine-related substitution treatment for opioid addicts research in Germany. Bernd Werse, deaths: a national 7 year study. in Germany - regulations at the federal Germany Shane Darke, Australia level: the revision of Germany’s legal framework. Kenan Maric-Horstmeyer, Germany STRUCTURED SESSION 18 STRUCTURED SESSION 19 STRUCTURED SESSION 20 20 years of ESPAD: trends in adolescents´ substance use and How the opioid problem is changing: the role of misused Wastewater-based drug epidemiology of illicit drugs, new risk behaviours, what have we learnt? medicines and the emergence of novel synthetic opioids psychoactive substances and the misuse of medication as a Chair: Julian Vicente, EMCDDA Chair: Paul Griffiths, EMCDDA and Moira O’Brien, NIDA supplement to traditional data-sources Chair: Barbara Kasprzyk-Hordern, United Kingdom − Are the times a-changin’? Trends in adolescent substance − Misuse of prescription opioids in Europe: an overview of − Review of the existing European network with summary of all use in Europe. Ludwig Kraus, Germany evidence and how it relates to prescribing practice from a data, and overview of future international programs. Kevin − Is there a link between perceived availability and use of European perspective. Cathy Stannard, United Kingdom Thomas, Australia alcohol, cannabis and cigarettes among young people in − The US opioid epidemic: a perspective on trends and − Comparison of data from WBE with other sources: A summary of Europe - cross-country and within country analyses of the responses from the U.S. National Drug Early Warning findings. Frederic Been, Belgium 2015 ESPAD-data. Håkan Leifman, Sweden System. Erin Artigiani, United States − Detection of New Psychoactive Substances (NPS) use across − Students at risk of substance use: Latent class risk and − Australian experience with opioids. Michael Farrell, Australia Europe. Sara Castiglioni, Italy protective factor profiles. Pavla Chomynova, Czech Republic − New synthetic opioids in Europe: perspective from the EU − The use of WBE for the detection of the misuse of medication. − Understanding the use of NPS by European students in the Early Warning System. Rita Jorge, EMCDDA Jørgen Bramness, Norway context of polysubstance use. Harry Sumnall, United − Review of the uncertainties in WBE. Christoph Ort, Switzerland Kingdom − Do misusers of medicinal psychotropic drugs form a distinctive group among the adolescent-student population in Europe? A latent class analysis. Anastasios Fotiou, Greece − Gambling, online gaming and illicit substance use among European students: A cross-national comparison. Sabrina Molinaro, Italy
10 / 20 Draft 28 July 2017
DAY 2 WEDNESDAY 25 OCTOBER
STRUCTURED SESSION 21 STRUCTURED SESSION 22 STRUCTURED SESSION 23 Online surveys of drug users: proceed with caution Political and ethical implications of the brain Reconceptualizing the etiology of substance Chair: Beau Kilmer, United States disease model of addiction use: implications for prevention and treatment Chair: Matilda Hellman, Finland Chair: Gregor Burkhart, EMCDDA − European Web Survey on Drugs: patterns of use. Nicola Singleton and João Matias, − Concepts and ideas on addiction: a historical − Panel discussion: EMCDDA perspective on great mergers. Johan Edman, Zili Sloboda, United States − Facebook ads for recruitment for online drug surveys: the Holy Grail? Dijana Jerković, Sweden Diana Fishbein, United States Croatia − Popular promises of progress: the articulation of Alessandro Pirona, EMCDDA − The Global Drug Survey (GDS): How online methods and independence offer alternative BDMA in the media. Anna Alanko and Matilda Gilberto Gerra, UNODC perspectives on drug use. Adam Winstock, United Kingdom and Larissa Meier, Switzerland Hellman, Finland − Reliability and validity issues in European web survey in Czech Republic. Katerina − The BDMA: Ethical and epistemological questions Skarupova, Czech Republic and considerations. Jaakko Kuorikoski and − Estimating cannabis demand: use of online surveys to capture use patterns. Margriet van Susanne Uusitalo, Finland Laar, Netherlands − Gambling and the brain. Janne Nikkinen, Finland
12:45 – 14:15 SPONSORED SESSIONS
Lunch boxes available between 12:30 and 14:30
12:45 – 14:15 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 28 PAPER SESSION 29 PAPER SESSION 30 PAPER SESSION 31 Spotlight on the misuse of medicines New methods Focus on pregnancy and the neonate Drug use and migration − A case study of anabolic-androgenic steroid − New perspectives for knowledge generation − Follow up of opioid exposed newborns untill − Can you develop problems with khat? Cross- dependence and treatment experiences. and exploitation using web surveys: the 3 years of age. Anna Maria Vella, Malta sectional and longitudinal studies to Ingrid Havnes and Johan Nygaard, Norway example of volume estimation in wastewater − Alcohol drinking in pregnancy: some determine the potential for clinically − Is misuse of benzodiazepines among high- epidemiology. Robin Udrisard, Switzerland predictors among Portuguese women. meaningful khat use disorder and withdrawal risk drug users an overlooked public health − High risk drug use and new psychoactive Ludmila Carapinha, Portugal syndromes. Raimondo Bruno, Australia issue? Dominique Lopez, India substances in Europe. Jane Mounteney, − Cannabis use during pregnancy and risk of − Social profiles, drug use practices and HCV − Medication use and misuse among illicit drug EMCDDA adverse birth outcomes: a longitudinal cohort exposure of Russian-speaking migrants in users in France. Aurélie Lermenier-Jeannet, − National estimation of the prevalence of study. Svetlana Skurtveit, Norway France. Marie Jauffret-Roustide, France France problem drug use: revisiting and extending − Neonatal outcomes after fetal exposure to − How ethnic is social recovery in problem − Gabapentin diversion and misuse in the multiplier methods in a multi-parameter opioid maintenance treatment. Blanka users with a migration background. Charlotte United States from a law enforcement evidence synthesis framework. Hayley Jones, Nechanska, Czech Republic de Kock, Belgium perspective: diversion rates 2002-2015 and United Kingdom
11 / 20 Draft 28 July 2017
DAY 2 WEDNESDAY 25 OCTOBER
qualitative research findings. Mance Buttram, − United States national drug early warning United States system (NDEWS): evolving drug early warning systems in a new world of drug production, distribution, and use. Erin Artigiani, United States − Development of a national wastewater drug monitoring program in Australia. Jake O´Brien, Australia
STRUCTURED SESSION 24 STRUCTURED SESSION 25 STRUCTURED SESSION 26 STRUCTURED SESSION 27 Take-home-naloxone: taking drug users No one gets left behind: addressing the hidden Targeting hard-to-reach client groups for Voices from the margins seriously burden of hepatitis C related advanced liver disease addiction aid in Switzerland - good Chair: Sarah Galvani, United Kingdom Chair: Thomas Clausen, Norway in PWID in the community in Dublin, Ireland practice in international perspective Chair: John Lambert, Ireland Chair: Petra Baumberger, Switzerland − Overdose deaths; diverging trends among − HepCheck: To enhance HCV screening of PWID. − Improvement of the support for − Transitions to long term recovery: developing heterogeneous groups of victims. Isabelle Geoff McCombe, Ireland addicted persons’ relatives – identities and sustainable change. Jo Ashby, Giraudon, EMCDDA − HepLink: To integrate primary and secondary Recommendations. Petra Baumberger, United Kingdom − New non-injectable naloxone products: global care by developing an integrated model of HCV Switzerland − Developing methodological identities: co- overview. Rebecca McDonald, United Kingdom care for PWID. Davina Swan, Ireland − Hard-to-reach target groups in production in addiction research. Lucy Webb, − Experiences from a national overdose − Hepfriend: Developing and cost evaluating a addiction aid – What efforts are already United Kingdom prevention strategy; nasal naloxone community peer support model to improve taken and what need for action − New psychoactive substances, new drug user distribution and lessons learned. Desiree access to HCV treatments for PWID. Nicola Perry, remains? Stefanie Knocks, Switzerland identities and new service provider Madah-Amiri, Norway Ireland − SafeZone.ch – online counselling on challenges. Rob Ralphs, United Kingdom − Opt-out vs opt-in: should take-home-naloxone addiction. Salomé Steinle, Switzerland − Who supports dying substance users? Drug be required as a safe clinical practice? John − Indebtedness process among using identities and end of life care. Sarah Strang, United Kingdom problematic gamblers. Oscar Ruiz, Galvani, United Kingdom − Take home naloxone as integral part of Switzerland toolkits for public health providers; priorities across settings. Dagmar Hedrich, EMCDDA − Drug user’s experience with take-home- naloxone; ’how I saved my friend‘; Short film
12 / 20 Draft 28 July 2017
DAY 2 WEDNESDAY 25 OCTOBER
14:30 – 16:00 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 32 PAPER SESSION 33 PAPER SESSION 34 PAPER SESSION 35 PAPER SESSION 36 The constructs of addiction Evaluating impact Developing effective drug treatment Perspectives on harm reduction Responding in the prison setting − Emotion regulation, − The evaluation of the alcohol law − What is the base for evidence-based − Take-home naloxone: − Anger management in detained addicts for attachment and addictive 2009 in Belgium. Tina Van Havere, treatment of opioid dependence? A pharmacokinetics of a novel nasal prevention of both crime and drug use: a behaviors. Paula Jauregui, Belgium systematic review of outcomes from spray in development in Europe. controlled cognitive behavioral trial in an Spain − The effect of criminal sanction on longitudinal observational studies. Rebecca McDonald, United Kingdom attenuate custody prison: a preliminary study. − Implicit associations in new psychoactive substance Lucas Wiessing, EMCDDA − Residential eviction and syringe Felice Nava, Italy male and female gamers supply reduction: a realist − Extrinsic and intrinsic factors in drug sharing among a prospective cohort − Drug use in prison: the role of peer educators across four different synthesis. Minqi Zhao, China treatment outcomes for persons in of street-involved youth. Andreas (8 years of intervention in a Portuguese prison online games are linked to − Adaption of the assist model of the criminal justice system: the roles Pilarinos, Canada setting). Andreia Nisa, Portugal symptoms of internet informal peer-led intervention of motivation and legal coercion. − The needle exchange debate in − Estimating the potential impact of providing gaming disorder. Christian delivery to the talk to frank drug Steven Belenko, United States Stockholm city council and Swedish HIV treatment and opioid agonist therapy Laier, Germany prevention programme in United − Reasons for abstaining in persons parliament during the 21st century. (OAT) in prison and upon release on HIV − Psychological and Kingdom secondary schools with long-term substance use Lena Eriksson, Sweden incidence among people who inject drugs neurobiological (ASSIST+FRANK): a pilot cluster disorders: a qualitative study. − The acceptability and feasibility of a (PWID) in Tijuana, Mexico. Annick Borquez, mechanisms underlying randomised controlled trial. James Henning Pettersen, Norway brief psychosocial intervention to United States the addictive use of White, United Kingdom − Utilisation of specialist psychiatric reduce blood borne virus risk − Modelling the role of incarceration in HCV specific internet − Assessment of drug treatment in health care services - 15 years behaviours among people who transmission and prevention amongst people applications. Matthias Croatia - results from cats follow-up of a Norwegian OMT- inject drugs: a randomised control who inject drugs in rural Kentucky. Jack Stone, Brand, Germany (Croatian addiction treatment cohort. Bent Monsbakken, Norway feasibility trial of a psychosocial United Kingdom − Implicit association and survey) and its implication on new − Profiles of individuals identified as intervention. Gail Gilchrist, United − The use of NPS in prison in Europe: what do craving towards shopping national drug policy strategy. having a substance use disorder and Kingdom we know? Consequences and responses. Linda cues in buying disorder. Zrinka Cavar, Croatia types of services received. Serge − The cost-effectiveness of needle and Montanari, EMCDDA Patrick Trotzke, Germany − An approach to disinvestment in Brochu, Canada syringe provision in preventing − Prison as a point of care for hepatitis c: the field of drug abuse. Antonella − Does exposure to opioid transmission of hepatitis C virus in recommendations based on strategic analysis Camposeragna, Italy substitution treatment at prison people who inject drugs. Zoe Ward, of population dynamics/ uptake of screening release reduce the risk of death? A United Kingdom in prisons in England and Wales. Nat Wright, prospective, observational study in − Evaluation of a drug checking United Kingdom England. Matthew Hickman, United integrated service: boom festival − Assessing the social acceptability of harm Kingdom 2016. Helena Valente, Portugal reduction scale-up in French prison settings: results from the ANRS-pride research. Marie Jauffret-Roustide, France
13 / 20 Draft 28 July 2017
DAY 2 WEDNESDAY 25 OCTOBER
STRUCTURED SESSION 28 STRUCTURED SESSION 29 STRUCTURED SESSION 30 STRUCTURED SESSION 31 Advancing hepatitis C care in people with a Harm reduction for people who inject drugs in Review of the effectiveness of treatment alternatives Health and social responses to drug history of injecting drugs/ opioid use disorder Europe: findings from three major European to incarceration for drug-involved persons problems in Europe: current state-of- (OUD) projects Chair: Roger Peters, United States the-art and future opportunities Chair: Carlos Roncero, Spain Chair: Mika Salminen, Finland Chair: Wayne Hall, Australia − Assessing the size of populations with injecting − HIV/HCV testing within low-threshold services. − Inter-American Drug Abuse Control Commission − Panel discussion: drug risk for chronic HCV infection. Jens Reimer, Alexandra Gurinova, Germany (CICAD) support to national and local governments Nicola Singleton, EMCDDA Germany − Health outcomes for clients of needle and in establishing drug treatment courts in Central and Dagmar Hedrich, EMCDDA − Barriers to treatment for HCV in OUD. What syringe programs in prisons: a systematic South America. Antonio Lomba, United States Marica Ferri, EMCDDA matters most? Nat Wright, United Kingdom review. Heino Stöver, Germany − The Portuguese system of community reintegration Alessandro Pirona, EMCDDA − Practical steps for HCV care in OUD populations: − No one gets left behind: Addressing the of drug-involved offenders from 1998 until 2015. Harry Sumnall, United Kingdom Results of a program to develop a best practice hidden burden of hepatitis C related advanced João Pedro Augusto, Portugal guide. Carlos Roncero, Spain liver disease in PWID in the community. John − Incarceration of drug-involved offenders in the − A vision for HCV and OUD in Europe. What Lambert, Ireland Czech Republic and in Europe, and need for should the overall strategy look like? Lorenzo − Community HIV testing in PWID: data from treatment-based alternatives. Michal Miovský, Somaini, Italy the COBATEST network. Laura Fernandez Czech Republic Lopez, Spain − Alternatives to incarceration developed through − Pilot condom distribution in a Czech prison. TASC programs in the U.S. Melody Heaps, United Viktor Mravcik, Czech Republic States − Harm reduction availability and accessibility in − Review of the effectiveness of treatment Europe – survey. Jeffrey Lazarus, Denmark alternatives to incarceration for drug-involved persons. Roger Peters, United States
16:00 – 16:30 Coffee break
16:30 – 18:00 PLENARY SESSION III BOUNDARIES OF ADDICTION Chair: Catherine Comiskey, Ireland Social construction of addiction. Henri Bergeron, France New vistas in basic, preclinical and translational addiction research. Rainer Spanagel, Germany Economic and conflict based rapid mass population movement into Europe: the security and public health implications for future EU drugs policy. Marie-Claire Van Hout, United Kingdom
2017 EMCDDA Scientific award ceremony
18:30 Conference dinner (pre-booking required)
14 / 20 Draft 28 July 2017
DAY 3 THURSDAY 26 OCTOBER
09:00 – 10:30 PLENARY SESSION IV CHALLENGES AHEAD Chair: Kerstin Stenius, Finland Extending definitions in addiction Joël Billieux, Luxembourg Challenges ahead for tobacco policies Ann McNeil, United Kingdom Challenges ahead for cannabis policies Beau Kilmer, United States
10:30 – 11:00 Coffee break
11:00 – 12:30 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 37 PAPER SESSION 38 PAPER SESSION 39 PAPER SESSION 40 PAPER SESSION 41 Illuminating the darknet and Gambling – assessment Understanding health consequences Innovations in practice The importance of gender online markets − Forensic drug intelligence and − Association of problem − The use of alcohol and drugs and its − Experiential avoidance and emotional − Insecure attachment and female drug the rise of darknet gambling with type of gambling. relation to the workplace. Cláudia dysregulation as therapeutic use. Efrat Fridman, United States marketplaces. Marie Morelato, Marco Scalese, Italy Urbano, Portugal dimensions in alcohol use disorder − Intimate partner violence in the past 12 Australia − Parents, peers, or promotion? − Cognitive bias modification treatment: findings based on 3-months months among men receiving treatment − Four years of monitoring Hannah Pitt, Australia targeting the cannabis and alcohol dialectical behavior therapy skills for substance use: prevalence, men’s cryptomarkets on the − Role of emotion dysregulation as consumption of youth in juvenile training. Marco Cavicchioli, Italy explanations and substances used at the darknet. Amanda Roxburgh, a predictor of pathological detention centers. Hans van der − Clinical strategies for engaging families time of the incident. Martha Canfield, Australia gambling and comorbid Baan, Netherlands of patients in substance addiction United Kingdom − “This place is like the jungle”. disorders. Paula Jauregui, Spain − One-year sobriety improves treatment programs: results from an − Men’s and women’s response to Discussion about NPS on a − Trajectories of gambling satisfaction with life, executive exploratory study with leading family treatment in a randomized controlled trial cryptomarket. Sara Rolando, behaviour and gambling functions and psychological distress therapists in the United States. of injectable opioid assisted treatment for Italy problems in outpatient care – among patients with polysubstance Sebastian Perumbilly, United States severe opioid use disorder. Heather Palis, − Purity, adulteration and price results from an ongoing study. use disorder. Egon Hagen, Norway − Building a bridge between prevention Canada of drugs bought on-line Ludwig Kraus, Germany − What can 20,000 people tell us research and practice: conclusions from − The prevalence and factors associated versus off-line in the − Gambling in Croatia (pilot about their recent nitrous oxide the long-term development and with ever perpetrating intimate partner Netherlands. Peggy van der project counties). Zrinka Puharić, (N2O) use? Understanding the implementation of the rebound life violence by men receiving substance use Pol, Netherlands Croatia recreational use of N2O and the skills and drug education programme. treatment in Brazil and England: a cross- − The role of the ‘dark web’ in − Core gambling-related traits and dose-response relationship with Maximilian von Heyden, Germany cultural comparison. Gail Gilchrist, United the trade of illicit drugs and their relationships with gambling myeloneuropathy. Jason Ferris, − Development of therapeutic alliance Kingdom the role of the Netherlands behavior patterns and severity: Australia and outcomes from the perspective of − Experiences and barriers of female drug on these marketplaces. Kristy an exploratory study with − Making cannabis safer: striking the drug users undergoing treatment in a users on alcohol and drug prevention and Kruithof, United Kingdom Ecuadorian gamblers. Marìa balance between THC and CBD. therapeutic community. Luís Janeiro, treatment in Belgium. Julie Schamp, Fernanda Jara Rizzo, Spain Amir Englund, United Kingdom Portugal Belgium
15 / 20 Draft 28 July 2017
DAY 3 THURSDAY 26 OCTOBER
− Symptoms and correlates of − Suicidal ideation among long-term opioid emergency medical treatment users: its risk factors and the role of following the use of MDMA (2014- gender. Kirsten Marchand, Canada 2016). Larissa Maier, Switzerland − Opioid using pregnant Maltese women. Anna Maria Vella, Malta STRUCTURED SESSION 32 STRUCTURED SESSION 33 STRUCTURED SESSION 34 STRUCTURED SESSION 35 Promoting a new era in global training and education Drug treatment expenditure: methodological Why are there more drug-related deaths: Addressing the unmet reproductive of addiction professionals: the international insights on proper measurement challenges for monitoring, understanding and health needs of women with consortium of universities for drug demand reduction Chair: Anne Line Breteville-Jensen, Norway preventing – examples from Europe addiction Chair: Michal Miovský, Czech Republic Chair: Isabelle Giraudon, EMCDDA Chair: Jan-Peter Siedentopf, Germany − Panel discussion: − A methodology for estimating health − Setting the European scene: Drug-related deaths − Panel discussion: Brian A. Morales, United States expenditure on drug treatment: the Australian in Europe: rebound and shifts? Brief update on a Mary Hepburn, United Kingdom Melody M. Heaps, United States experience. Alison Ritter, Australia diverse picture. Isabelle Giraudon, EMCDDA Natanya Robinowitz, United States Roger H. Peters, United States − Estimating the costs of substitution therapy − A review of triggers and drivers of drug-related Mishka Terplan, United States Zili Sloboda, United States for heroin and opioid addiction in the United deaths in seven northern European countries. − Titles to be confirmed. Jeff Lee, United Kingdom States: Insights and challenges. Rosalie Pacula, Tim Millar and Andrew Mc Auley, United Kingdom Amalie Pavlovská, Czech Republic United States − Estimations of trends, effects of changes in − Titles to be confirmed. − A methodology for an EU cross-country recording practices and studies of drug pattern. comparison: public expenditure on drug Focus on Sweden. Håkan Leifman, Sweden treatment in hospitals. Freya Vander Laenen, − Preventing drug-related deaths: Policy Belgium implications and ways forward. Focus on Norway. − Social cost in France: What’s new if the field of Thomas Clausen, Norway death toll and illness calculations. Pierre Kopp, − A different perspective from Australia. Shane France Darke, Australia Discussant: Cláudia Costa Storti, EMCDDA STRUCTURED SESSION 36 STRUCTURED SESSION 37 STRUCTURED SESSION 38 Anonymous collecting and testing of NPS samples as a part of Best practices in HCV prevention, management and treatment among Drug research and drug monitoring in prison national early warning systems (EWS) people who inject drugs Chair: Heino Stöver, WEPHREN and Linda Montanari, Chair: Simona Šabić, Slovenia Chair: Alexis Goosdeel, EMCDDA and Matthew Hickman, United Kingdom EMCDDA − Anonymous collection and testing of NPS samples as a part of − Model and empirical evidence on the effectiveness of interventions to − WHO minimum public health data set on prison national EWS: challenges and advantages. Andreja Drev, Slovenia prevent HCV among people who inject drugs. Matthew Hickman, health. Lars Møller, WHO-Regional Office for − Establishment of NGO info points for NPS sample collection United Kingdom Europe within regional EWS system in the framework of I-SEE project. − Direct-acting interferon-free therapies and reinfection among people − European Questionnaire on Drug Use among Ada Hočevar Grom, Slovenia who inject drugs. Jason Grebely, Australia Prisoners – EQDP. Viktor Mravcik, Czech Republic
16 / 20 Draft 28 July 2017
DAY 3 THURSDAY 26 OCTOBER
− The integrated drug checking service and its importance for − Restrictions for reimbursement of interferon-free direct-acting − Prison history - drug-related problems in people different types of users. Simona Šabić, Slovenia antiviral therapies for HCV infection in Europe. Jeffrey Lazarus, who inject drugs. Lucas Wiessing, EMCDDA − Establishment of drug checking service in MSM community: Denmark − Spanish survey on health and drug use among things to be considered. Miran Šolinc, Slovenia (tbc) prisoners. Elena Alavarez, Spain − Monitoring drug use in custodial institutions for juvenile offenders in Portugal. Ludmila Carapinha, Portugal − French system on drug monitoring in prison. Marie Jauffret-Roustide, France
Lunch boxes available between 12:30 and 14:30
12:45 – 14:15 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 42 PAPER SESSION 43 PAPER SESSION 44 Spotlight on drug consumption rooms Analysis to inform service development and delivery Improving the evidence base on HCV − Drug consumption rooms: issues of social and political − Screening of drug use in primary care services in Catalonia, feasibility − Detachable low dead-space syringes for the acceptability in French public debate. Marie Jauffret-Roustide, analysis of the assist tool. Joan Colom i Farran, Spain prevention of hepatitis C among people who France − Improving treatment outcome by adding different structural elements inject drugs in Bristol, England: an economic − Influencing drug policy: making the case for medically to outpatient substance abuse treatment programs offered to Danish evaluation. Peter Vickerman, United Kingdom supervised injecting facilities in Dublin. Tony Duffin, Ireland youth. Mads Uffe Pedersen and Sheila Jones, Denmark − Early HCV treatment and HCV case finding in − Drug consumption rooms in Porto, Portugal: listening to the − The Portuguese DSM-IV-MR-J: validation of an instrument to measure people who inject drugs (PWID): cost- concerned voices. Paula Meireles, Portugal youth problem gambling to the Portuguese language. Joana Alexandre, effectiveness studies. Matthew Hickman, United − Frequency and severity of non-fatal opioid overdoses among Portugal Kingdom clients attending the Sydney medically supervised injecting − Evaluating the integration of indigenous healing practices with − HCV treatment as prevention in Europe: model centre. Amanda Roxburgh, Australia principles of seeking safety for treatment of indigenous patients with a projections and impact of current and scaled-up − Drug consumption rooms in Catalonia: major impact on HIV- history of trauma and active substance use disorder. Teresa Marsh, treatment rates. Hannah Fraser, United Kingdom HCV risk behaviors and engagement in care. Cinta Folch, Spain Canada − Restrictions for reimbursement of interferon-free − Factors concerning access to a potential drug consumption − The efficacy of mindfulness-based treatments for alcohol and drugs use direct-acting antiviral therapies for HCV infection room in Dublin, Ireland. Emma Atkin-Brenninkmeyer, Ireland disorders: a critical meta-analytic review of randomized and non- in Europe. Jeffrey Lazarus, Denmark randomized controlled trials. Marco Cavicchioli, Italy
17 / 20 Draft 28 July 2017
DAY 3 THURSDAY 26 OCTOBER
STRUCTURED SESSION 39 STRUCTURED SESSION 40 STRUCTURED SESSION 41 STRUCTURED SESSION 42 STRUCTURED SESSION 43 The stigma of addiction and its Ayahuasca – why is Prevention: from evidence to action – how we The universal prevention curriculum Promoting the use of evidence- impacts on healthcare. classification so important? are working. (UPC) adaptation in Europe: introduction based programmes in Europe: a Chair: Karsten Lunze, United States Chair: Mário Simões, Portugal Chair: Joaquim Fonseca, Portugal and discussion on substantial content. European registry. Chair: Annemie Coone, Belgium Chair: Gregor Burkhart, EMCDDA − Stigma among people who use − Ethnical uses of Ayahuasca. − School-based drug use prevention − Why is a common training curriculum − Panel discussion: drugs. Jason Luoma, Valerie Tania Re, Italy and Jorge multicomponent model: a Lisbon and Tagus for Europe needed? Annemie Coone, Marica Ferri, EMCDDA Earnshaw and Patrick Corrigan, Martins, Portugal Valley Region Perspective. Isabel Prata, Belgium Gregor Burkhart, EMCDDA United States − Ayahuasca’s therapeutic Portugal − Getting to the UPC-curriculum and Frederick Groeger-Roth, Germany − The stigma of unhealthy alcohol potential in drug addiction. − ‘Me and the Others’ programme: building projecting this content on the Nick Axford, United Kingdom use. Georg Schomerus and Mário Simões and José Palma, standards-based narratives for prevention. participants own context. Sanela Talic, Shreya Sonthalia, United Nicolas Rüsch, United States Portugal Raúl Melo, Portugal Slovenia, Katarzina Okulicz, Poland, and Kingdom − Understanding and intervening − Pharmacology of Ayahuasca. − ‘Me and Others’ Programme – Outcome Maria Antónia Gomila, Spain Fabrizio Faggiano, Italy on addiction stigma. Magdalena Olga Silva, Portugal Evaluation: Lisbon and Tagus Valley Region − Substance use prevention training Zili Sloboda, United States Kozena and Karsten Lunze, − Ayahuasca uncertain legal sample (2015 to 2017). Pre, post and follow needs found in the involved countries United States status. Sofia Machado, up. Carla Frazão, Portugal and local prevention training needs of Portugal − ‘Guidelines to deal with addictive the participants. Annemie Coone, behaviours’. Project, process and outcome Belgium and Antónia Katarzyna Okulicz, evaluation. Rui Pedro Silva, Portugal Poland
14:30 – 16:00 PARALLEL SESSIONS (see separate document for poster sessions)
PAPER SESSION 45 PAPER SESSION 46 PAPER SESSION 47 PAPER SESSION 48 PAPER SESSION 49 Interconnected problems - spotlight on Innovative methods Gambling – informing interventions Innovation in harm reduction The challenge of responding in comorbidity recreational settings − Is problematic internet use associated − Wastewater analysis: source of − Documenting the strategies and − Illegal and legal substance abuse − Social representations of with general psychological distress in information about the relation tactics used by the Australian amongst harm reduction program users - drugs and drug abuse. Inquiry young people? Findings from an between frequently abused illicit gambling industry. A case study of a case study from Croatia. Dalibor to the Portuguese youth Italian representative sample of digital drugs and music genre preferences. clubs, casinos and the wagering Dolezal, Croatia present in three editions of natives. Valeria Siciliano, Italy Paula Brandeburová, Slovakia industry. Samantha Thomas, − Drug checking - an approach to prevent Rock in Rio summer festival − Investigating possible causal − Representativeness challenges for Australia chemical anarchy: a scoping review. (2008/2012/2016). Vasco associations of tobacco and cannabis web surveys collecting information − Stigma and the involvement of Helena Valente, Portugal Calado, Portugal use with mental health: a Mendelian on drug users: a way for improving people with gambling addiction in − Chemsex, NPS and risk reduction − Stop SV: staff training on randomisation analysis. Meg Fluharty, the cannabis market estimation in peer support and advocacy management: preliminary results of a prevention of sexual violence. United Kingdom France. François Beck, France activities. Helen Miller, Australia pilot study. Cécile Chevallier, France Fernando Mendes, Portugal
18 / 20 Draft 28 July 2017
DAY 3 THURSDAY 26 OCTOBER
− Drug-related predictors of − The European drug emergencies − The role of gambling advocacy − Harm reduction 24/7: the supply of harm − A randomized trial of readmission for schizophrenia among network (Euro-DEN) project – a strategies in gambling harm reduction materials via vending machines assessment interventions to patients admitted to treatment for model for European data collection prevention and minimisation for drug users in Northrhine-Westfalia, reduce drug use and HIV/STI drug use disorders. Kristine Rømer on acute drug and new strategies. Jennifer David, Australia Germany. Daniel Deimel, Germany sexual risk among young Thomsen, Denmark psychoactive substance (NPS) − Parents, peers, or promotion? Which − Disciplining pleasure through harm adults who use drugs in the − Sex differences in psychiatric disorders toxicity. Paul Dargan, United factors are the most influential in reduction policy: confronting drug users’ club scene. Steven Kurtz, among illicit drug users. Gail Gilchrist, Kingdom shaping children’s attitudes towards personal experience of injection in United States United Kingdom − The analysis of illicit drugs in gambling? Hannah Pitt, Australia context with professionals’ public health − How often do ecstasy users in − Alcohol- and drug-related problems Sydney wastewater. Anne − Jegspiller.no - a new prevention tool expectations. Marie Jauffret-Roustide, nightlife implement harm among adolescents with psychiatric Bannwarth, Switzerland for problems related to gambling France reduction strategies? Peggy diagnoses: the role of psychiatric − Temporal trends and subjective and gaming. Jarle Wangen, Norway − Alcohol consumption among party goers van der Pol, Netherlands comorbidity. Ove Heradstveit, Norway highness for alternative cannabis − Maladaptive metacognitive beliefs attending university parties. Samples from − Health consequences of − Father involvement and correlates of product use reported in an online in pathological gambling: three years of harm reduction substance use in nightlife symptoms of depression and anxiety cannabis community. Meredith relationship with addictive behaviors interventions in the field (2014 to 2016 in settings in the Netherlands. among fathers with drug addiction Meacham, United States and comorbid symptomatology. the region of Lisbon and Tagus valley). Karin Monshouwer, problems. João Barrocas, Portugal Paula Jauregui, Spain Marta Borges, Portugal Netherlands STRUCTURED SESSION 44 STRUCTURED SESSION 45 STRUCTURED SESSION 46 STRUCTURED SESSION 47 STRUCTURED SESSION 48 Nightlife: no risk no fun? challenges Continuum of care in the prison setting? Crystal meth and the family – stress, strain, Multidisciplinary work in a scientific GRADE evidence to decision for drug prevention and Responses to drug-related infection and interventions society of addictions framework for the EMCDDA trendspotting transmission in prisons – examples from Chair: Michael Klein, Germany Chair: Francisco Pascual, Spain Best practice portal Chair: Gregor Burkhart, EMCDDA Europe Chair: Elena Parmelli, Italy Chair: Dagmar Hedrich, EMCDDA − Drug use in European recreational − Drug use and drug-related infections − Establishing an integrated perinatal care − A sociological study on alcohol − The Best practice portal. settings: mixing contexts, risks and among prisoners. Linda Montanari, program for substance-dependent young and cannabis use among young Marica Ferri, EMCDDA pleasure. João Matias, EMCDDA EMCDDA mothers. Ulrich Zimmermann, Germany people in Spain. Gerardo Florez, − The DECIDE Project. Marina − Environmental prevention in − Access to harm reduction – the example − Living situation of children from Spain Davoli, Italy nightlife settings. Johanna of France. Laurent Michel, France methamphetamine-involved families. − Socidrogalcohol Spanish national − A practical example of Gripenberg, Sweden − Access to HCV treatment under special Michael Klein, Germany survey on prevalence and application of the GRADE − Protecting and promoting health consideration in prisons – action research − Parenting stress and familial coping in treatment of co-ocurrence of EtD framework to a Best in nightlife environments during Austria. Gabriele Fischer, Austria the context of parental substance use disorder and other practice portal topic. Elena the last three decades. Andrew − New joint European guidance on methamphetamine use. Janina Dyba, mental health disorder. Juan José Parmelli, Italy Bennett, United Kingdom responding to communicable diseases in Germany Fernández, Spain − Zurich’s integrated nightlife prison – focus on drug use-related − SHIFT – A parenting intervention for − The RINCA Study Study on the approach. Alexander Bücheli, infections. Lara Tavoschi, Sweden methamphetamine abusing mothers and Reduction of Negative Incidences Switzerland fathers. Diana Moesgen, Germany associated to excessive Alcohol
19 / 20 Draft 28 July 2017
DAY 3 THURSDAY 26 OCTOBER
− Emerging trends within nightlife − Treatment of methamphetamine addicts Consumption. Josep Guardia, settings: responses and innovation. in clinical practice. Katharina Schoett, Spain Sarah Morton, Ireland Germany
16:00 – 16:30 Coffee break
16:30 Closing session, including closing keynote
ORGANISERS
INTERNATIONAL ORGANISATIONS
COLLABORATIVE PARTNERS
SUPPORTING ORGANIZATIONS
20 / 20 Draft 28 July 2017